Shatha Farhan
YOU?
Author Swipe
View article: MicroRNA-mediated metabolic control in HCC: From molecular networks to therapy
MicroRNA-mediated metabolic control in HCC: From molecular networks to therapy Open
Hepatocellular carcinoma (HCC) is the most common histological subtype of primary liver cancer, accounting for nearly 80-90 % of all liver cancer cases. While 'liver cancer' refers broadly to all malignant tumors arising in the liver (incl…
View article: US Geriatric Assessment Practices for Older Adults Undergoing Hematopoietic Cell Transplantation or Chimeric Antigen Receptor T Cell Therapy: An American Society for Transplantation and Cellular Therapy Physician Survey from the Aging Special Interest Group and Committee on Practice Guidelines
US Geriatric Assessment Practices for Older Adults Undergoing Hematopoietic Cell Transplantation or Chimeric Antigen Receptor T Cell Therapy: An American Society for Transplantation and Cellular Therapy Physician Survey from the Aging Special Interest Group and Committee on Practice Guidelines Open
Geriatric assessment (GA) may identify vulnerabilities and promote risk-stratification in older adults predisposed to toxicities after autologous (auto), allogeneic (allo) hematopoietic cell transplantation (HCT) and chimeric antigen T-cel…
View article: CHARACTERIZING BREAST CANCER STAGES ON THE BASIS OF CORRELATION
CHARACTERIZING BREAST CANCER STAGES ON THE BASIS OF CORRELATION Open
Aim of the study was to characterize the different stages of breast cancer and their role inearlydiagnosis and prognosis.Qualitative data in different stagesof breast cancer showed maximum cases of stage3 (T3) n= 85 among all stages. Out o…
View article: Second Infusion of CAR T-Cells in Patients with Relapsed /Refractory B-Cell Acute Lymphoblastic Leukemia: Results from a Gocart Coalition Analysis on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT
Second Infusion of CAR T-Cells in Patients with Relapsed /Refractory B-Cell Acute Lymphoblastic Leukemia: Results from a Gocart Coalition Analysis on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT Open
Background: The prognosis of patients (pts) with relapsed or refractory B ALL (r/r B-ALL) treated with CAR T-cells and receive a 2nd CART infusion is unknown. Few reports with limited numbers of patients suggest that 2nd CART infusion is f…
View article: Real-World Outcomes of CD19-Targeted CAR T-Cell Therapy in Adult and Pediatric Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Insights from the GoCART Coalition on Behalf of the PDWP, ALWP, and CTIWP of the EBMT
Real-World Outcomes of CD19-Targeted CAR T-Cell Therapy in Adult and Pediatric Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Insights from the GoCART Coalition on Behalf of the PDWP, ALWP, and CTIWP of the EBMT Open
Background: In 2015 the first B-cell acute lymphoblastic leukemia (B-ALL) patient receiving CAR T-cell therapy in Europe was reported to the EBMT registry. Today, the EBMT registry counts with more than 9000 patients treated with CAR T-cel…
View article: Ciprofloxacin versus levofloxacin prophylaxis in hematopoietic stem cell transplantation: A randomized trial
Ciprofloxacin versus levofloxacin prophylaxis in hematopoietic stem cell transplantation: A randomized trial Open
This study is registered on ClinicalTrials.gov, NCT03850379.
View article: CD19-directed CART therapy for T-cell/histiocyte–rich large B-cell lymphoma
CD19-directed CART therapy for T-cell/histiocyte–rich large B-cell lymphoma Open
T-cell/histiocyte–rich large B-cell lymphoma (THRLBCL) is a rare histologic variant of LBCL. Limited data regarding CD19–directed chimeric antigen receptor T-cell (CART) therapy in relapsed/refractory (R/R) THRLBCL suggest poor efficacy. W…
View article: Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study
Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study Open
We evaluate the impact of donor types on outcomes of hematopoietic cell transplantation (HCT) in myelofibrosis, using the Center for International Blood and Marrow Transplant Research registry data for HCTs done between 2013 and 2019. In a…
View article: Graft-versus-host disease: teaching old drugs new tricks at less cost
Graft-versus-host disease: teaching old drugs new tricks at less cost Open
Graft-versus-host disease (GVHD) remains a major cause of morbidity and mortality after allogeneic stem cell transplantation (SCT). Currently, more patients can receive SCT. This is attributed to the use of reduced intensity regimens and t…
View article: Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis
Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis Open
Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only curative treatment for myelofibrosis. However, the optimal conditioning regimen either with reduced-intensity conditioning (RIC) or myeloablative conditioning (MAC) …
View article: A Single Institution Randomized Clinical Trial Evaluating Ciprofloxacin Versus Levofloxacin As Antibacterial Prophylaxis for Patients Receiving Hematopoietic Stem Cell Transplantation
A Single Institution Randomized Clinical Trial Evaluating Ciprofloxacin Versus Levofloxacin As Antibacterial Prophylaxis for Patients Receiving Hematopoietic Stem Cell Transplantation Open
Chronic nicotine administration impairs reflex chronotropic responses that follow arterial baroreceptor unloading in female rats with repleted, but not depleted (ovariectomized, OVX), estrogen (E2). This study investigated whether products…
View article: Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes
Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes Open
Reduced-intensity conditioning (RIC) regimens developed to extend the use of allogeneic hematopoietic stem cell transplantation (HSCT) to older patients have resulted in encouraging outcomes. We aimed to compare the 2 most commonly used RI…
View article: Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants
Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants Open
Key Points Compared with parous female sibling donors, male URDs confer more aGVHD in all patients and more cGVHD in females. There was no difference in survival, relapse, or transplant mortality between recipients of parous female sibling…
View article: Outcome of Non-Germinal Center/Activated B-Cell Type Diffuse Large B-Cell Lymphoma Determined by IHC in a Single Institution Over 7 Years
Outcome of Non-Germinal Center/Activated B-Cell Type Diffuse Large B-Cell Lymphoma Determined by IHC in a Single Institution Over 7 Years Open
Background: The classification of diffuse large B cell lymphoma takes into consideration the cell of origin (COO), germinal center B-cell (GCB) versus non-germinal center/activated B-cell type (non-GCB/ABC), since its determination by gene…
View article: Busulfan Pharmacokinetics and CD4 Reconstitution after Stem Cell Transplant in Patients with Myeloid Neoplasms
Busulfan Pharmacokinetics and CD4 Reconstitution after Stem Cell Transplant in Patients with Myeloid Neoplasms Open
Background: In recipients of allogeneic stem cell transplant, T-cell recovery is crucial to regain immune competence. Antithymocyte globulin (ATG) and fludarabine have been shown to influence CD4+ T-cell recovery. To explore the impact of …
View article: Horsies and Bunnies: A Comparison of Antithymocyte Globulin in Allogeneic Stem Cell Transplant
Horsies and Bunnies: A Comparison of Antithymocyte Globulin in Allogeneic Stem Cell Transplant Open
Background: Graft versus host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplant (HSCT). In vivo T-cell depletion includes antithymocyte globulin (ATG) such as ATG-Horse or ATG-Rabbit used in combinatio…
View article: Early Donor Chimerism in Patients with Myeloid Malignancies Undergoing Stem Cell Transplantation Using FluBu4 with and Without Busulfan Pharmacokinetics Compared to Busulfan and Cyclophosphamide
Early Donor Chimerism in Patients with Myeloid Malignancies Undergoing Stem Cell Transplantation Using FluBu4 with and Without Busulfan Pharmacokinetics Compared to Busulfan and Cyclophosphamide Open
The impact of early donor cell chimerism on outcomes of reduced toxicity conditioning regimens and allogeneic stem cell transplantation (SCT) in myeloid disorders is ill defined. To explore the impact of busulfan pharmacokinetics (Bu PK) o…
View article: Chimerism in Myeloid Malignancies following Stem Cell Transplantation Using FluBu4 with and without Busulfan Pharmacokinetics versus BuCy
Chimerism in Myeloid Malignancies following Stem Cell Transplantation Using FluBu4 with and without Busulfan Pharmacokinetics versus BuCy Open
In the era of precision medicine, the impact of personalized dosing of busulfan is not clear. We undertook a retrospective analysis of 78 patients with myeloid malignancies who received fludarabine and busulfan (FluBu4) with or without mea…
View article: Impact of Cytomegalovirus on Early Chimerism in Patients with Myeloid Disorders Undergoing Stem Cell Transplantation Using Reduced Toxicity Ablative Conditioning Regimen
Impact of Cytomegalovirus on Early Chimerism in Patients with Myeloid Disorders Undergoing Stem Cell Transplantation Using Reduced Toxicity Ablative Conditioning Regimen Open
The influence of Cytomegalovirus (CMV) on chimerism in reduced toxicity ablative allogeneic stem cell transplantation (SCT) in myeloid disorders is ill defined. A recent report by Sellar et al showed that in patients who received alemtuzum…
View article: Emberger Syndrome with Concomitant GATA2, NPM1 and FLT3-ITD Mutations in Remission after Allogeneic Stem Cell Transplant
Emberger Syndrome with Concomitant GATA2, NPM1 and FLT3-ITD Mutations in Remission after Allogeneic Stem Cell Transplant Open
GATA2 mutation has previously been described in several phenotypically diverse disorders including familial myelodysplasia/AML and Emberger syndrome. It has also been linked to other entities such as pulmonary alveolar proteinosis, hypothy…
View article: Choice of Unmanipulated T Cell Replete Graft for Haploidentical Stem Cell Transplant and Posttransplant Cyclophosphamide in Hematologic Malignancies in Adults: Peripheral Blood or Bone Marrow—Review of Published Literature
Choice of Unmanipulated T Cell Replete Graft for Haploidentical Stem Cell Transplant and Posttransplant Cyclophosphamide in Hematologic Malignancies in Adults: Peripheral Blood or Bone Marrow—Review of Published Literature Open
Allogeneic hematopoietic stem cell transplantation (SCT) is often the only curative option for many patients with malignant and benign hematological stem cell disorders. However, some issues are still of concern regarding finding a donor l…